Drug intelligence / Profile preview

Abexol

Development stage
Unknown
Lead developer
Centro Nacional de Investigaciones Científicas
Modality
Small Molecules
Administration
Oral
01

Overview

Abexol is a natural product-based nutritional supplement developed by the Centro Nacional de Investigaciones Científicas (CNIC) in Cuba, in collaboration with Laboratorio Farmacéutico de Líquidos Orales (Medilip). It is composed of a purified mixture of six high-molecular-weight primary fatty alcohols (ranging from 24 to 34 carbon atoms) extracted from beeswax (*Apis mellifera*). The product is administered orally and is available in tablet (50 mg) and suspension formulations. Abexol functions primarily as an antioxidant, preventing the oxidation of lipids and proteins, and exhibits gastroprotective and anti-inflammatory properties. It is approved in Cuba for managing oxidative stress, gastric conditions (such as gastritis and ulcers), and joint disorders (such as osteoarthritis). The product is part of the BioCubaFarma portfolio.

Brand names
Abexol
Other names
beeswax alcoholspurified beeswax alcohols
02

Targets

COXALOX12 (Arachidonate 12-lipoxygenase, 12S type)

Beyond the preview

Go deeper on Abexol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abexol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call